Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aura BiosciencesAURA -2.08%35 3-Year RORE % is -2.18 as of Mar. 2026. GuruFocus rates AURA with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 1,291 Biotechnology companies, Aura Biosciences ranks better than 61.58% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Aura Biosciences's 3-Year RORE % for the quarter that ended in Mar. 2026 was -2.18%.
The industry rank for Aura Biosciences's 3-Year RORE % or its related term are showing as below:
AURA's 3-Year RORE % is ranked better than 61.58% of 1291
companies
in the Biotechnology industry
Industry Median: -11.55
vs AURA: -2.18
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Aura Biosciences 3-Year RORE % Related Terms
Aura Biosciences 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Aura Biosciences's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aura Biosciences's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aura Biosciences 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aura Biosciences's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Aura Biosciences's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Aura Biosciences (AURA) has a 3-Year RORE % of -2.18 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Aura Biosciences and its competitors. According to the industry distribution chart, Aura Biosciences ranks #496 out of 1291 companies in the Biotechnology industry, placing it in the top 38.4%.
Is Aura Biosciences' 3-Year RORE % too high?
Aura Biosciences' current 3-Year RORE % is -2.18. Based on the distribution chart, Aura Biosciences ranks #496 out of 1291 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aura Biosciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Aura Biosciences' 3-Year RORE % compare to NVCT and CADL?
According to the Biotechnology industry distribution chart, Aura Biosciences ranks #496 out of 1291 companies for 3-Year RORE %. This puts Aura Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Aura Biosciences and its competitors. Aura Biosciences's current 3-Year RORE % is -2.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aura Biosciences stock overvalued right now?
Aura Biosciences (AURA) has a current 3-Year RORE % of -2.18. The current 3-Year RORE % is -2.18. Aura Biosciences' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Aura Biosciences (AURA), the current 3-Year RORE % is -2.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
35GF Score
Get the complete analysis for AURA
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AURA has been successfully added to your 
